Biotech

Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial

Biotech

CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that clinical data from the company’s Phase 2a study of its lead candidate, AKB-9778, for the treatment of patients with DME, have been published in an article titled “Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation …

CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on

MARKETS

Markets
TSX20714.48+13.98
TSXV622.01+0.87
DOW33978.08+28.67
S&P 5004070.56+10.13
NASD11621.71+109.30
ASX7493.80+25.50

COMMODITIES

Commodities
Gold1927.96+0.24
Silver23.60+0.01
Copper4.23-0.04
Palladium1713.170.00
Platinum1087.260.00
Oil79.38-1.63
Heating Oil3.19-0.11
Natural Gas2.85-0.09

DOWNLOAD FREE REPORTS

×